Moleculin Biotech, Inc. (MBRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
MBRX Stock Price Chart Interactive Chart >
MBRX Price/Volume Stats
| Current price | $1.27 | 52-week high | $2.05 |
| Prev. close | $1.29 | 52-week low | $0.82 |
| Day low | $1.24 | Volume | 21,300 |
| Day high | $1.32 | Avg. volume | 51,111 |
| 50-day MA | $1.26 | Dividend yield | N/A |
| 200-day MA | $1.38 | Market Cap | 36.36M |
Moleculin Biotech, Inc. (MBRX) Company Bio
Moleculin Biotech, Inc., a preclinical and clinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company was founded in 2015 and is based in Houston, Texas.
Latest MBRX News From Around the Web
Below are the latest news stories about MOLECULIN BIOTECH INC that investors may wish to consider to help them evaluate MBRX as an investment opportunity.
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19thJTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, January 17-19, 2023. |
Moleculin to Present at the Virtual Investor 2023 Companies to Watch EventMoleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January 17, 2023 at 9:00 AM ET. |
Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced it has received approval from the Agenzia Italiana del Farmaco (AIFA, the Italian Medicines Agency competent authority) and the Istituto Superiore di Sanità (ISS, the Italian National Institute of Health) for its Phase 1/2 trial evaluating Annamycin in combination with Cytarabine (Ara-C |
Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |
Moleculin Biotech's Annamycin In Leukemia Study Shows 80% Overall Response RateMoleculin Biotech Inc (NASDAQ: MBRX) provided an update on its clinical programs evaluating Annamycin for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. The data exhibited an 80% overall response rate (ORR) in the final cohort (n=5) of the European trial of Annamycin as a single agent with one CRi (complete response with incomplete recovery of peripheral blood count) and three PRs (Partial Response). Of 42 subjects in three of the company's Ann |
MBRX Price Returns
| 1-mo | 12.39% |
| 3-mo | 28.32% |
| 6-mo | -23.95% |
| 1-year | -9.93% |
| 3-year | -75.50% |
| 5-year | -89.47% |
| YTD | 19.81% |
| 2022 | -43.01% |
| 2021 | -61.11% |
| 2020 | -12.89% |
| 2019 | -12.01% |
| 2018 | -44.09% |
Loading social stream, please wait...